Diflucan 150 mg (Fluconazole)

Adult dosage

The route of administration should be determined according to the patient's clinical condition. Because oral formulations are rapidly and almost completely absorbed, the doses of oral formulations (tablets, capsules, dry syrup) and injectable formulations are the same. ○ Adults 1. Vaginal candidiasis: Administer a single 150 mg oral dose of fluconazole. 2. Systemic candidiasis, including candidemia, disseminated candidiasis, and other invasive Candida infections (peritoneal, endocardial, pulmonary, urinary tract, etc.): The usual dose of this medicine is 400 mg once on the first day, followed from the next day by 200 mg once daily; depending on the patient's response, the dose may be increased to 400 mg once daily. The duration of treatment should be determined according to clinical response and medical judgment. 3. Cryptococcal meningitis and cryptococcosis at other sites: The usual dose of this medicine is 400 mg once on the first day, followed from the next day by 200-400 mg once daily. The duration of treatment is determined by the clinical and mycological response, but treatment should generally be given for at least 6 ~ 8 weeks. 4. To prevent recurrence of cryptococcal meningitis in patients with AIDS, after the patient has completed primary treatment, administer 200 mg of this medicine once daily indefinitely. 5. Prevention of fungal infections in immunocompromised patients at risk due to neutropenia caused by cytotoxic chemotherapy, radiation therapy, or bone marrow transplantation: Administer 50-400 mg of this medicine once daily, depending on the patient's risk of fungal infection. A dose of 400 mg once daily is recommended for patients at very high risk of systemic fungal infections, such as those undergoing bone marrow transplantation with severe neutropenia or an expected prolonged period of neutropenia. In these patients, administer 400 mg starting 5-6 days before the expected onset of neutropenia and continue administering 400 mg for 1 week after the neutrophil count increases to 1,000 cells/mm3 or higher. 6. For onychomycosis, administer 150 mg once weekly until the fingernails or toenails regrow (until new, uninfected nails grow). It usually takes 3-6 months for a new fingernail to grow and 6-12 months for a toenail; the growth rate may vary by individual and age. In some cases, even after successful treatment with long-term administration, the fingernails or toenails may remain damaged. For skin fungal infections, including athlete's foot (tinea pedis), tinea corporis, jock itch (tinea cruris), and cutaneous candidiasis: The usual dose of this medicine is 50 mg once daily or 150 mg once weekly for 2-4 weeks. However, athlete's foot may require treatment for 6 weeks, depending on the course. For tinea versicolor, administer 50 mg once daily for 2-4 weeks. ○ Older adults If renal function is normal, the usual adult dose is administered. In patients with renal impairment (creatinine clearance 50 mL/min or less), the dose should be reduced or the dosing interval extended. ○ Patients with renal impairment This medicine is excreted mainly in the urine unchanged. No dose adjustment is needed for a single dose; however, when multiple doses are required, administer the usual dose only on the first day and adjust the dose from the following day as follows. Creatinine clearance (mL/min) Recommended dose > 50 ≤50 (not on dialysis) Patients on hemodialysis 100% of the usual dose 50% of the usual dose 100% of the usual dose after each hemodialysis session Patients on hemodialysis should receive 100% of the usual dose after each hemodialysis session. On days without dialysis, administer a reduced dose according to creatinine clearance.

This medication should not be administered to certain patients. For example, it should not be used by patients who have had hypersensitivity reactions to this medication or other azole medications, women who are pregnant or may become pregnant, and nursing mothers. Moreover, serious side effects may occur when taken with certain medications, so patients on these medications should also avoid this drug. This medication contains lactose; therefore, it should not be administered to patients with lactose intolerance or related genetic disorders. It should be used cautiously in patients with impaired kidney or liver function, a history of drug hypersensitivity, heart disease, or electrolyte disturbances that may pose a risk for arrhythmias. In addition, since this medication strongly inhibits certain enzymes, caution is required when used with other medications metabolized by these enzymes, and the patient's condition should be closely monitored. Generally, this drug is well tolerated, but in rare cases, abnormalities in blood, liver, or kidney functions may occur, and skin rashes or serious skin reactions may develop. Also, side effects such as headache, dizziness, dyspepsia, abdominal pain, diarrhea, and vomiting may occur, so if symptoms are severe, consult a physician. During pregnancy, the use of this medication might be harmful to the fetus; thus, women planning to become pregnant or who are pregnant should avoid its use and effective contraception should be practiced during treatment. In the case of nursing, since this medication is excreted in breast milk, it is advisable not to use it. Safety regarding infants, particularly those under 6 months of age, has not been established, and it should be used cautiously only if necessary. Dizziness or seizures may occur while taking this medication, so caution is advised when driving or operating machinery. In case of overdose, hallucinations or abnormal behavior may manifest, so immediate medical attention should be sought, and if necessary, hemodialysis can be used to lower the serum concentration of this medication.

Agranulocytosis, leukopenia, neutropenia, thrombocytopenia, anaphylaxis, angioedema, hypertriglyceridemia, hypercholesterolemia, hypokalemia, insomnia, drowsiness, headache, seizures, dizziness, paresthesia, dysgeusia, tremor, vertigo, Torsades de pointes, QT prolongation, abdominal pain, diarrhea, nausea, vomiting, dyspepsia, abdominal bloating, dry mouth, increased ALT, increased AST, elevated serum alkaline phosphatase, cholestasis, jaundice, increased bilirubin, hepatotoxicity, liver failure, hepatocellular necrosis, hepatitis, hepatocellular damage, rash, pruritus, urticaria, increased sweating, drug rash, toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, exfoliative dermatitis, facial edema, hair loss, drug reaction with eosinophilia and systemic symptoms, myalgia, fatigue, malaise, asthenia, fever, adrenal insufficiency, hallucinations, psychotic behavior

This medication may be sensitive to air or moisture and should be stored in a tightly closed container. It is recommended to maintain a storage temperature between 1°C and 30°C to safely preserve the efficacy of the medication.

Appearance

Pink rectangular tablet

Package unit

30 tablets/bottle